The ASCO/CAP-recommended ERBB2/HER2 testing criteria for BC was updated, and a threshold of 10% and an ERBB2/CEN17 ratio of ≥2.0 were introduced in 2013 to ensure that the appropriate patients received the ERBB2-targeted drug [40]. This evidence concerns the gene ERBB2 and breast cancer.